Costs of tuberculosis disease in the European Union: A systematic analysis and cost calculation

European Respiratory Journal

Volumn 43, Issue 2, 2014, Pages 554-565

  Diel, Roland ^a   Vandeputte, Joris ^b   De Vries, Gerard ^c,d   Stillo, Jonathan ^e   Wanlin, Maryse ^f   Nienhaus, Albert ^g  

^a UNIVERSITY HOSPITAL SCHLESWIG HOLSTEIN   (Germany)

^b Trivarop SPRL ^*  (Belgium)

^c KNCV TUBERCULOSIS FOUNDATION   (Netherlands)

^d NATIONAL INSTITUTE FOR PUBLIC HEALTH AND THE ENVIRONMENT   (Netherlands)

^e CITY UNIVERSITY OF NEW YORK   (United States)

^f Belgian Lung and Tuberculosis Association   (Belgium)

^g UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ANTITUBERCULAR AGENTS; EUROPEAN UNION; EXTENSIVELY DRUG-RESISTANT TUBERCULOSIS; HEALTH CARE COSTS; HUMANS; MYCOBACTERIUM TUBERCULOSIS; POPULATION SURVEILLANCE; QUALITY-ADJUSTED LIFE YEARS; TUBERCULOSIS; TUBERCULOSIS, MULTIDRUG-RESISTANT;

EID: 84893513006     PISSN: 09031936     EISSN: 13993003     Source Type: Journal    
DOI: 10.1183/09031936.00079413     Document Type: Article

References (57)

1. Diel R, Nienhaus A. Prevention of TB in areas of low incidence. In: Lange C, Migliori GB, eds. Tuberculosis. Eur Respir Monogr 2012; 58: 72-83.
2. Kaufmann SH. Fact and fiction in tuberculosis vaccine research: 10 years later. Lancet Infect Dis 2011; 11: 633-640.
3. Brennan MJ, Stone MR, Evans T. A rational vaccine pipeline for tuberculosis. Int J Tuberc Lung Dis 2012; 16: 1566-1573.
4. Ottenhoff TH, Kaufmann SH. Vaccines against tuberculosis: where are we and where do we need to go. PLoS Pathog 2012; 8: e1002607.
5. Parliamentary Questions: answer given by Ms Geoghegan-Quinn on behalf of the Commission. E9505/2010. www. europarl.europa.eu/sides/getAllAnswers.do? Reference5E-2010-9505&language5FI Date last accessed: March 15, 2013. Date last updated: September 9, 2011.
6. Tuberculosis Vaccine Initiative (TBVI). Translating Science into Products through Innovative Funding A Contribution to a Healthier World and an Innovative Europe by Developing new TB vaccines. Lelystad, TBVI, 2011.
7. European Academies Science Advisory Council. Drug-Resistant Tuberculosis: Challenges, Consequences and Strategies for Control. London, EASAC, 2009.
8. Loddenkemper R, Gibson GJ, Sibille Y, eds. European Lung White Book: the First Comprehensive Survey on Respiratory Health in Europe. Sheffield, European Respiratory Society Journals, 2003.
9. van der Werf MJ, Langendam MW, Sandgren A, et al. Lack of evidence to support policy development for management of contacts of multidrug-resistant tuberculosis patients: two systematic reviews. Int J Tuberc Lung Dis 2012; 16: 288-296.
10. D'Ambrosio L, Centis R, Migliori GB. Multidrug-resistant tuberculosis. N Engl J Med 2012; 367: 2154.
11. World Health Organization. Global Tuberculosis Control 2012. Geneva, World Health Organization, 2012.
12. European Centre for Disease Prevention and Control and World Health Organization Regional Office for Europe. Surveillance Report: Tuberculosis Surveillance and Monitoring in Europe 2012. Stockholm, European Centre for Disease Prevention and Control, 2012.
13. World Health Organization. Global Tuberculosis Report 2012. Geneva, World Health Organization, 2012.
14. Skrahina A, Hurevich H, Zalutskaya A, et al. Alarming levels of drug-resistant tuberculosis in Belarus: results of a survey in Minsk. Eur Respir J 2012; 39: 1425-1431.
15. Migliori GB, Dara M, de Colombani P, et al. Multidrug-resistant tuberculosis in Eastern Europe: still on the increase? Eur Respir J 2012; 39: 1290-1291.
16. World Health Organization. Global Tuberculosis Control 2011. Geneva, World Health Organization, 2011.
17. World Health Organization Regional Office for Europe. Consolidated Action Plan to Prevent and Combat Multidrug- and Extensively Drug-Resistant Tuberculosis in the WHO European Region 2011-2015. www.euro. who.int/-data/assets/pdf-file/0007/147832/wd15E-TB-ActionPlan-111388.pdf Date last accessed: March 15, 2013. Date last updated: July 21, 2011.
18. European Centre for Disease Prevention and Control and World Health Organization Regional Office for Europe. Tuberculosis Surveillance and Monitoring in Europe 2013. Stockholm, European Centre for Disease Prevention and Control, 2013.
19. Falzon D, Gandhi N, Migliori GB, et al. Resistance to fluoroquinolones and second-line injectable drugs: impact on multidrug-resistant TB outcomes. Eur Respir J 2013; 42: 156-168.
20. Migliori GB, Sotgiu G, Gandhi NR, et al. Drug resistance beyond extensively drug-resistant tuberculosis: individual patient data meta-analysis. Eur Respir J 2013; 42: 169-179.
21. Veen J, Migliori GB, Raviglione M, et al. Harmonisation of TB control in the WHO European region: the history of the Wolfheze Workshops. Eur Respir J 2011; 37: 950-959.
22. Broekmans JF, Migliori GB, Rieder HL, et al. European framework for tuberculosis control and elimination in countries with a low incidence. Recommendations of the World Health Organization (WHO), International Union Against Tuberculosis and Lung Disease (IUATLD) and Royal Netherlands Tuberculosis Association (KNCV) Working Group. Eur Respir J 2002; 19: 765-775.
23. European Centre for Disease Prevention and Control. Progressing Towards TB Elimination. A follow-up to the Framework Action Plan to Fight Tuberculosis in the European Union. Stockholm, European Centre for Disease Prevention and Control, 2010.
24. Diel R, Loddenkemper R, Zellweger JP, et al. Old ideas to innovate tuberculosis control: preventive treatment to achieve elimination. Eur Respir J 2013; 42: 785-801.
25. Diel R, Goletti D, Ferrara G, et al. Interferon-c release assays for the diagnosis of latent Mycobacterium tuberculosis infection: a systematic review and meta-analysis. Eur Respir J 2011; 37: 88-99.
26. Sester M, Sotgiu G, Lange C, et al. Interferon-c release assays for the diagnosis of active tuberculosis: a systematic review and meta-analysis. Eur Respir J 2011; 37: 100-111.
27. Skripconoka V, Danilovits M, Pehme L, et al. Delamanid improves outcomes and reduces mortality in multidrugresistant tuberculosis. Eur Respir J 2013; 41: 1393-1400.
28. De Lorenzo S, Alffenaar JW, Sotgiu G, et al. Efficacy and safety of meropenem-clavulanate added to linezolidcontaining regimens in the treatment of MDR-/XDR-TB. Eur Respir J 2013; 41: 1386-1392.
29. Alsaad N, van Altena R, Pranger AD, et al. Evaluation of co-trimoxazole in the treatment of multidrug-resistant tuberculosis. Eur Respir J 2013; 42: 504-512.
30. European Central Bank. Harmonised Indices of Consumer Prices, Breakdown by Purpose of Consumption. www. ecb.int/stats/prices/hicp/html/hicp-coicop-anr- 2013-02.en.html Date last accessed: March 15, 2013. Date last updated: February 2013.
31. Prüss-Üstün A, Mathers C, Corvalán C, et al. Assessing the Environmental Burden of Disease at National and Local Levels. WHO Environmental Burden of Disease Series, No.1. Geneva, World Health Organization, 2003.
32. World Health Organization. Global Burden of Disease: 2004 Update. Geneva, World Health Organisation, 2008.
33. AEA Technology Environment. Methodology Paper (Volume 2) for Service Contract for Carrying out Cost-Benefit Analysis of Air Quality Related Issues, in particular in the Clean Air for Europe (CAFE) Programme. Available from: http://cafe-cba.aeat.com/assets/volume-2-methodology-overview-02-05.pdf Oxon, AEA Technology, 2005.
34. GHK. A Study on Liability and the Health Costs of Smoking: Updated Final Report. London, GHK, 2012. Available from: http://ec.europa.eu/health/tobacco/ docs/tobacco-liability-final-en.pdf.
35. White VL, Moore-Gillon J. Resource implications of patients with multidrug resistant tuberculosis. Thorax 2000; 55: 962-963.
36. Deuffic-Burban S, Atsou K, Viget N, et al. Cost-effectiveness of QuantiFERON-TB test vs. tuberculin skin test in the diagnosis of latent tuberculosis infection. Int J Tuberc Lung Dis 2010; 14: 471-481.
37. French National Assembly. Information Report. Annex No 3: Coûts comparés du traitement médicamenteux de la tuberculose en France [Cost comparison of drug treatment of tuberculosis in France]. www.assemblee-nationale.fr/ 13/rap-info/i3524.asp#P1623-331406 Date last accessed: March 15, 2013.
38. Bocchino M, Greco S, Rosati Y, et al. Cost determinants of tuberculosis management in a low-prevalence country. Int J Tuberc Lung Dis 2006; 10: 146-152.
39. Montes-Santiago J, Fernández C, Rey G, et al. Hospitalizaciones por tuberculosis en España: análisis de sus costes [Tuberculosis-related hospitalization in Spain: a cost analysis]. Enferm Infecc Microbiol Clin 2010; 28: 358-361.
40. Rajalahti I, Ruokonen EL, Kotomäki T, et al. Economic evaluation of the use of PCR assay in diagnosing pulmonary TB in a low-incidence area. Eur Respir J 2004; 23: 446-451.
41. Diel R, Rutz S, Castell S, et al. Tuberculosis: cost of illness in Germany. Eur Respir J 2012; 40: 143-151.
42. Blaas SH, Mütterlein R, Weig J, et al. Extensively drug resistant tuberculosis in a high income country: a report of four unrelated cases. BMC Infect Dis 2008; 8: 60.
43. Eker B, Ortmann J, Migliori GB, et al. Multidrug- and extensively drug-resistant tuberculosis, Germany. Emerg Infect Dis 2008; 14: 1700-1706.
44. de Vries G, Baltussen R. Kosten van tuberculose en TBC-bestrijding in Nederland [Cost of tuberculosis and tuberculosis control in the Netherlands]. Tegen Tuber 2013; 109: 3-7.
45. Rumetshofer R. Multiresistente Tuberkulose - ein Weltweites Problem [Multidrug-resistant tuberculosis - a worldwide problem]. Jatros Infektiologie 2008; 4: 20-22.
46. Floyd K, Hutubessy R, Kliiman K, et al. Cost and cost-effectiveness of multidrug-resistant tuberculosis treatment in Estonia and Russia. Eur Respir J 2012; 40: 133-142.
47. Department of Health. Supply of TB drugs to patients - changes to regulations and advice on implementation. http://webarchive.nationalarchives. gov.uk/+/www.dh.gov.uk/en/Publichealth/Communicablediseases/Tuberculosis/ DH-078136 Date last accessed: March 15, 2013. Date last updated: June 16, 2009.
48. Belgian Lung and Tuberculosis Association. BELTA TBnet Rapport, 2012. www.belta.be/content/view/71/217/ lang,french Date last accessed: March 15, 2013.
49. World Health Organization. Guidelines for the Programmatic Management of Drug-Resistant Tuberculosis, Emergency Update, 2008. Geneva, World Health Organization, 2008.
50. Falzon D, Jaramillo E, Schünemann HJ, et al. WHO guidelines for the programmatic management of drug-resistant tuberculosis: 2011 update. Eur Respir J 2011; 38: 516-528.
51. World Health Organization. Estonia. Estimates of Unit Costs for Patient Services in Estonia. www.who.int/choice/ country/est/cost/en/ Date last accessed: March 15, 2013.
52. European Hospital Morbidity Database. http://data.euro.who.int/hmdb/ cbparams.php Date last accessed: March 15, 2013. Date last updated: November, 2013.
53. Eurostat European Commission. Basic Figures on the EU: Spring 2013 Edition. Brussels, European Union, 2013. Available from: http://epp.eurostat.ec. europa.eu/cache/ITY-OFFPUB/KS-GL-13-001/EN/KS-GL-13-001-EN.PDF.
54. Farrell D, Jensen E, Kocher B, et al. Accounting for the Cost of US Health Care: A New Look At Why Americans Spend More. McKinsey Global Institute, 2008. Available from: www.academyhealth.org/files/2009/monday/Jensene.pdf.
55. Eurostat. Life Expectancy at Birth, 1980-2011 (years).png. http://epp.eurostat.ec.europa.eu/statistics-explained/index.php?title5File: Life-expectancy-at-birth,-1980-2011-%28years%29.png& filetimestamp520130129120827 Date last accessed: March 15, 2013. Date last updated: January 29, 2013.
56. National Institute for Health and Clinical Excellence. Tuberculosis: Clinical Diagnosis and Management of Tuberculosis, and Measures for its Prevention and Control. Costing Report. Implementing NICE Guidance in England. NICE clinical guideline no. 33, March 2006. Available from: www.nice.org.uk/ nicemedia/pdf/CG033CostingReport.pdf.
57. Migliori GB, Zellweger JP, Abubakar I, et al. European Union standards for tuberculosis care. Eur Respir J 2012; 39: 807-819.